Pharmacogenetics and drug-induced arrhythmias.
Drugs are widely recognized to vary in the beneficial and undesirable effects they produce in human subjects. The understanding that variants (polymorphisms and mutations) in the human genome are common and may well modulate both disease and its response to drugs, is a critical new concept in understanding mechanisms of drug action and their variability in human subjects. Variability can arise because of variability in genes encoding molecules of drug disposition, in genes encoding molecules that drugs target, or in genes that modulate the overall activity of the complex biological systems within which drugs act. The evolving understanding of the genetic basis of variability in response to drugs used in the treatment of sudden cardiac death has important implications not only for the treatment of patients who have survived an episode, but also for helping formulate a framework for further understanding mechanisms of drug action at the genetic level.
Roden
D M
DM
Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 532 Medical Research Building I, Nashville, TN 37232, USA. dan.roden@mcmail.vanderbilt.edu
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D010597:Pharmacogenetics
D000889:Anti-Arrhythmia Agents